World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
86
Citations
34351
World Ranking
1236
National Ranking
645

Medicine

D-Index
86
Citations
34596
World Ranking
13939
National Ranking
7074

Overview

Marcela V. Maus is affiliated with Harvard University in the United States. Their primary field of study is Medicine, with a focus on Oncology, Immunology, Molecular Biology, Genetics, and Biomedical Engineering. The concentration of their research is particularly strong in the area of oncology, supported by a significant number of publications in related fields.

The scientist's research covers several main topics, including:

  • CAR-T cell therapy research
  • Nanowire Synthesis and Applications
  • Immune Cell Function and Interaction
  • Virus-based gene therapy research
  • Biosimilars and Bioanalytical Methods
  • Viral Infectious Diseases and Gene Expression in Insects
  • CRISPR and Genetic Engineering

Marcela V. Maus has frequently collaborated with other researchers in the field. Notable co-authors include:

  • Matthew J. Frigault
  • Mark B. Leick
  • Rebecca C. Larson
  • Kathleen Gallagher
  • Amanda A. Bouffard

The scientist has published extensively across various reputable venues. The most frequent publication venues include:

  • Blood
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Among their recent papers are several notable publications such as:

  • "Recent advances and discoveries in the mechanisms and functions of CAR T cells," published in 2021 in Nature Reviews. Cancer
  • "The Emerging Landscape of Immune Cell Therapies," published in 2020 in Cell
  • "PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial," published in 2022 in Nature Medicine
  • "Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies," published in 2020 in The Lancet
  • "Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity," published in 2020 in Journal of Clinical Oncology

Best Publications

  • ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    Daniel W. Lee;Bianca D. Santomasso;Frederick L. Locke;Armin Ghobadi

  • A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

    Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst

  • Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

  • Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

    Gregory L. Beatty;Andrew R. Haas;Marcela V. Maus;Drew A. Torigian

  • Antibody-modified T cells: CARs take the front seat for hematologic malignancies

    Marcela V. Maus;Stephan A. Grupp;Stephan A. Grupp;David L. Porter;Carl H. June

  • CD8(+) T-cell responses to adeno-associated virus capsid in humans.

    Federico Mingozzi;Marcela V Maus;Marcela V Maus;Daniel J Hui;Denise E Sabatino

  • Recent advances and discoveries in the mechanisms and functions of CAR T cells.

    Rebecca C. Larson;Marcela V. Maus

  • Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

    Alfred L. Garfall;Marcela V. Maus;Wei-Ting Hwang;Simon F. Lacey

  • Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing.

    Benjamin P. Kleinstiver;Alexander A. Sousa;Russell T. Walton;Y. Esther Tak

  • T cells expressing chimeric antigen receptors can cause anaphylaxis in humans

    Marcela V. Maus;Andrew R. Haas;Gregory L. Beatty;Steven M. Albelda

  • Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

    Marcela V. Maus;Anna K. Thomas;Debra G.B. Leonard;David Allman

  • Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

    Li Tang;Yiran Zheng;Mariane Bandeira de Melo;Llian Mabardi

  • PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

    Unknown

  • Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

    Christopher C. Kloss;Jihyun Lee;Aaron Zhang;Fang Chen

  • CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

    Bryan D Choi;Xiaoling Yu;Ana P Castano;Amanda A Bouffard

  • Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

    Laura A. Johnson;John Scholler;Takayuki Ohkuri;Akemi Kosaka

  • Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

    Joseph A. Fraietta;Kyle A. Beckwith;Prachi R. Patel;Marco Ruella

  • CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

    Unknown

  • The Emerging Landscape of Immune Cell Therapies.

    Evan W. Weber;Marcela V. Maus;Crystal L. Mackall

  • Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells

    Mathias Oelke;Marcela V. Maus;Dominic Didiano;Carl H. June

  • Engineering and Design of Chimeric Antigen Receptors

    Sonia Guedan;Hugo Calderon;Avery D. Posey;Avery D. Posey;Marcela V. Maus

  • Ibrutinib treatment improves T cell number and function in CLL patients

    Meixiao Long;Kyle Beckwith;Priscilla Do;Bethany L. Mundy

Frequent Co-Authors

Carl H. June
Carl H. June University of Pennsylvania
Bruce L. Levine
Bruce L. Levine University of Pennsylvania
Simon F. Lacey
Simon F. Lacey University of Pennsylvania
Katherine A. High
Katherine A. High Children's Hospital of Philadelphia
Hideho Okada
Hideho Okada University of California, San Francisco
James L. Riley
James L. Riley University of Pennsylvania
J. Joseph Melenhorst
J. Joseph Melenhorst University of Pennsylvania
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Federico Mingozzi
Federico Mingozzi Children's Hospital of Philadelphia
David L. Porter
David L. Porter University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in delving deeper into Immunology, several related online degrees can expand your career opportunities in healthcare and research. Many professionals begin with a nursing foundation, and there are excellent options like online adn programs for non nurses that welcome students without prior nursing experience.

If you’re seeking an accelerated route, programs identified as the easiest absn program to get into can offer a streamlined path to becoming a registered nurse, crucial for many immunology-related roles. Likewise, exploring accredited lpn programs easy to get into provides a practical entry point into nursing, with flexible online options to fit busy schedules.

For advanced practice opportunities, the easiest nurse practitioner program options allow for specialization that often includes immunology or infectious disease care. These pathways not only enhance clinical skills but also open doors to leadership and research roles in immunology.

Best Scientists Citing Marcela V. Maus

Trending Scientists

Recently Published Articles